Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | HIV Therapy Dynamics

HIV Therapy Dynamics

"IntroductionDespite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.ScopeCurrent epidemiology of HIV in the six major markets, including prevalence, diagnosis rates and patients split by line of therapy and drug regimens A detailed examination of the patient numbers on each line of therapy, their drug regimens and preferences Evaluation of the factors determining prescription choices and their respective level of influence An assessment of the perception of new products in development and of key unmet needs within HIVHighlightsIn the US and M5EU the total number of people living with HIV is continuing to increase. According to Datamonitor's physician survey, the total number of diagnosed patients across the 6MM is 1.1 million, of which 18% are treatment-naïve and approx. 800.000 are currently receiving therapy The complexity of HAART begins to increase as patients progress to later stages of therapy, with regimens consisting of up to 6 different drugs. Treatment also becomes much more individualized: Datamonitor's research shows that the top 5 most popular regimens selected by physicians account for only 13% of patients in salvage therapy Prescription choice is largely driven by patient and product-specific qualities, but the influence of these issues varies according to line of therapy. Efficacy and resistance profile exert an increasing influence as the patient becomes more treatment-experienced.Reasons to PurchaseIdentify the key factors underlying prescription choice for treatment of HIV Examine the current unmet needs in the HIV market and identify opportunities for new product development Enhance your commercial positioning through an improved understanding of the HIV market dynamics"

08-Oct-07 Format: PDF & SlidePack Pages: 190
Table of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions